<--- Back to Details
First PageDocument Content
Boehringer Ingelheim / Duloxetine / Eli / Lilly / Chemistry / Dendreon / Eli Lilly and Company / Indiana / Pharmaceutical industry
Date: 2013-05-21 21:43:02
Boehringer Ingelheim
Duloxetine
Eli
Lilly
Chemistry
Dendreon
Eli Lilly and Company
Indiana
Pharmaceutical industry

seen on the most sites For the second straight year, Janssen’s oral anticoagulant Xarelto was the most widely advertised branded drug on sites tracked by Kantar’s Evaliant tool (last year it tied for the top spot wit

Add to Reading List

Source URL: media.mmm-online.com

Download Document from Source Website

File Size: 260,67 KB

Share Document on Facebook

Similar Documents

About Advanced Prostate Cancer Treatment Options Resources Prostate Cancer Navigator

About Advanced Prostate Cancer Treatment Options Resources Prostate Cancer Navigator

DocID: 1oTjG - View Document

BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS  THURSDAY MARCH 15, 2012  VOLUME 23 , NO. 51

BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS THURSDAY MARCH 15, 2012 VOLUME 23 , NO. 51

DocID: 19ZND - View Document

Developing GMP IPS Lines - Identifying and Eliminating Roadblocks Mahendra Rao, M.D., Ph.D., (former) Director NIH CRM, Laboratory of Stem Cell Biology Chief,  The Path to Personalized Medicine

Developing GMP IPS Lines - Identifying and Eliminating Roadblocks Mahendra Rao, M.D., Ph.D., (former) Director NIH CRM, Laboratory of Stem Cell Biology Chief, The Path to Personalized Medicine

DocID: 14kRG - View Document

Medicare to pay for $93,000 prostate cancer drug

Medicare to pay for $93,000 prostate cancer drug

DocID: Rsxd - View Document

seen on the most sites For the second straight year, Janssen’s oral anticoagulant Xarelto was the most widely advertised branded drug on sites tracked by Kantar’s Evaliant tool (last year it tied for the top spot wit

seen on the most sites For the second straight year, Janssen’s oral anticoagulant Xarelto was the most widely advertised branded drug on sites tracked by Kantar’s Evaliant tool (last year it tied for the top spot wit

DocID: O0pR - View Document